Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Reproducible automated breast density measure with no ionizing radiation using fat-water decomposition MRI.

Ding J, Stopeck AT, Gao Y, Marron MT, Wertheim BC, Altbach MI, Galons JP, Roe DJ, Wang F, Maskarinec G, Thomson CA, Thompson PA, Huang C.

J Magn Reson Imaging. 2018 Apr 6. doi: 10.1002/jmri.26041. [Epub ahead of print]

PMID:
29630755
2.

Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore?

Stopeck AT.

Cancer. 2017 Jul 1;123(13):2392-2394. doi: 10.1002/cncr.30678. Epub 2017 May 2. No abstract available.

3.

Response to letter to the Editors-Safety of long-term denosumab therapy.

Stopeck AT, Warner DJ.

Support Care Cancer. 2017 Feb;25(2):353-355. doi: 10.1007/s00520-016-3492-8. Epub 2016 Nov 24. No abstract available.

4.

Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.

Lipton A, Smith MR, Fizazi K, Stopeck AT, Henry D, Brown JE, Shore ND, Saad F, Spencer A, Zhu L, Warner DJ.

Clin Cancer Res. 2016 Dec 1;22(23):5713-5721. Epub 2016 May 2.

5.

Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.

Brown-Glaberman U, Marron M, Chalasani P, Livingston R, Iannone M, Specht J, Stopeck AT.

Dis Markers. 2016;2016:9810383. doi: 10.1155/2016/9810383. Epub 2016 Jan 28.

6.

A maximum-likelihood method to estimate a single ADC value of lesions using diffusion MRI.

Jha AK, Rodríguez JJ, Stopeck AT.

Magn Reson Med. 2016 Dec;76(6):1919-1931. doi: 10.1002/mrm.26072. Epub 2016 Jan 7.

7.

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Smith MR, Shore N, Martin M, Vadhan-Raj S, Brown JE, Richardson GE, Saad F, Yardley DA, Zhou K, Balakumaran A, Braun A.

Eur J Cancer. 2016 Jan;53:75-83. doi: 10.1016/j.ejca.2015.09.011. Epub 2015 Dec 13.

8.

Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A.

Support Care Cancer. 2015 Oct 19. [Epub ahead of print] No abstract available.

PMID:
26482379
9.

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A.

Support Care Cancer. 2016 Jan;24(1):447-55. doi: 10.1007/s00520-015-2904-5. Epub 2015 Sep 3. Erratum in: Support Care Cancer. 2015 Oct 19;:.

10.

Diffusion MRI with Semi-Automated Segmentation Can Serve as a Restricted Predictive Biomarker of the Therapeutic Response of Liver Metastasis.

Stephen RM, Jha AK, Roe DJ, Trouard TP, Galons JP, Kupinski MA, Frey G, Cui H, Squire S, Pagel MD, Rodriguez JJ, Gillies RJ, Stopeck AT.

Magn Reson Imaging. 2015 Dec;33(10):1267-1273. doi: 10.1016/j.mri.2015.08.006. Epub 2015 Aug 15.

11.

The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.

Diel IJ, Body JJ, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, von Moos R, Goldwasser F, Feng A, Braun A.

Eur J Cancer. 2015 Jul;51(11):1467-75. doi: 10.1016/j.ejca.2015.04.017. Epub 2015 May 11.

PMID:
25976743
12.

A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer.

Chalasani P, Marron M, Roe D, Clarke K, Iannone M, Livingston RB, Shan JS, Stopeck AT.

Cancer Med. 2015 Jul;4(7):1051-9. doi: 10.1002/cam4.447. Epub 2015 Mar 31.

13.

Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models.

Chen LQ, Howison CM, Spier C, Stopeck AT, Malm SW, Pagel MD, Baker AF.

Leuk Lymphoma. 2015 May;56(5):1432-9. doi: 10.3109/10428194.2014.933218. Epub 2014 Nov 10.

14.

Impact of denosumab on bone mass in cancer patients.

Brown-Glaberman U, Stopeck AT.

Clin Pharmacol. 2013 Jul 4;5:117-29. doi: 10.2147/CPAA.S30330. Print 2013.

15.

Reply to Araki et al.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Braun AH.

Eur J Cancer. 2013 Jun;49(9):2266-8. doi: 10.1016/j.ejca.2013.02.037. Epub 2013 Apr 8. No abstract available.

PMID:
23578571
16.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S.

Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.

PMID:
22975218
17.

A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.

Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP.

Blood. 2012 Aug 9;120(6):1210-7. doi: 10.1182/blood-2012-04-423079. Epub 2012 Jun 25.

18.

Task-based evaluation of segmentation algorithms for diffusion-weighted MRI without using a gold standard.

Jha AK, Kupinski MA, Rodríguez JJ, Stephen RM, Stopeck AT.

Phys Med Biol. 2012 Jul 7;57(13):4425-46. doi: 10.1088/0031-9155/57/13/4425. Epub 2012 Jun 20. Erratum in: Phys Med Biol. 2013 Jan 7;58(1):183.

19.

The role of targeted therapy and biomarkers in breast cancer treatment.

Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS.

Clin Exp Metastasis. 2012 Oct;29(7):807-19. doi: 10.1007/s10585-012-9496-y. Epub 2012 Jun 13. Review.

PMID:
22692561
20.

Prevalence of depression in adults with haemophilia.

Iannone M, Pennick L, Tom A, Cui H, Gilbert M, Weihs K, Stopeck AT.

Haemophilia. 2012 Nov;18(6):868-74. doi: 10.1111/j.1365-2516.2012.02863.x. Epub 2012 May 30.

PMID:
22642565
21.

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.

Brown-Glaberman U, Stopeck AT.

Biologics. 2012;6:89-99. doi: 10.2147/BTT.S20677. Epub 2012 Apr 12.

22.

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.

Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN.

Breast Cancer Res Treat. 2012 Jul;134(1):13-20. doi: 10.1007/s10549-011-1918-z. Epub 2011 Dec 24.

23.

Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.

Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, Ibrahim NK.

Clin Cancer Res. 2011 Nov 1;17(21):6888-96. doi: 10.1158/1078-0432.CCR-11-1074. Epub 2011 Oct 11.

24.

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P, Dansey R.

Ann Oncol. 2012 May;23(5):1341-7. doi: 10.1093/annonc/mdr435. Epub 2011 Oct 10.

PMID:
21986094
25.

How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?

Gralow JR, Lipton A, Stopeck AT.

J Clin Oncol. 2011 Sep 10;29(26):3591-2; author reply 3592-3. doi: 10.1200/JCO.2011.36.5759. Epub 2011 Aug 15. No abstract available.

PMID:
21844502
26.

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D.

J Clin Oncol. 2011 Jun 20;29(18):2459-65. doi: 10.1200/JCO.2010.31.2975. Epub 2011 May 9.

PMID:
21555686
27.

Evaluating segmentation algorithms for diffusion-weighted MR images: a task-based approach.

Jha AK, Kupinski MA, Rodríguez JJ, Stephen RM, Stopeck AT.

Proc SPIE Int Soc Opt Eng. 2010 Feb 27;7627. pii: 76270L (2010).

28.

A Clustering Algorithm for Liver Lesion Segmentation of Diffusion-Weighted MR Images.

Jha AK, Rodríguez JJ, Stephen RM, Stopeck AT.

Proc IEEE Southwest Symp Image Anal Interpret. 2010 May 23;2010:93-96.

29.

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A.

J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8.

PMID:
21060033
30.

Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs. reduced carbohydrate diets.

Thomson CA, Stopeck AT, Bea JW, Cussler E, Nardi E, Frey G, Thompson PA.

Nutr Cancer. 2010;62(8):1142-52. doi: 10.1080/01635581.2010.513803.

PMID:
21058203
31.

Caring for the breast cancer survivor: a guide for primary care physicians.

Chalasani P, Downey L, Stopeck AT.

Am J Med. 2010 Jun;123(6):489-95. doi: 10.1016/j.amjmed.2009.09.042. Review.

PMID:
20569749
32.

Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial.

Thompson PA, Hsu CH, Green S, Stopeck AT, Johnson K, Alberts DS, Chow HH.

Cancer Prev Res (Phila). 2010 Jan;3(1):101-7. doi: 10.1158/1940-6207.CAPR-09-0120.

33.

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.

Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP.

Leuk Lymphoma. 2009 May;50(5):728-35. doi: 10.1080/10428190902856808.

34.

Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia.

Gerstner G, Damiano ML, Tom A, Worman C, Schultz W, Recht M, Stopeck AT.

Haemophilia. 2009 Mar;15(2):559-65. doi: 10.1111/j.1365-2516.2008.01963.x. Epub 2009 Feb 1.

PMID:
19187193
35.

A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer.

Gordon MS, Mendelson D, Carr R, Knight RA, Humerickhouse RA, Iannone M, Stopeck AT.

Cancer. 2008 Dec 15;113(12):3420-9. doi: 10.1002/cncr.23953.

36.

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA.

J Clin Oncol. 2007 Dec 1;25(34):5410-7.

PMID:
18048823
37.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA.

Blood. 2007 Jun 15;109(12):5136-42. Epub 2007 Mar 7.

38.

Women's health: the struggle to restore hormonal balance.

Stopeck AT.

Am J Med. 2005 Nov;118(11):1181-2. No abstract available. Erratum in: Am J Med. 2006 Feb;119(2):191.

PMID:
16271897
39.

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.

O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louie SG, Hong W, Stopeck AT, Silverman LR, Lancet JE, Karp JE, Albitar M, Cherrington JM, Giles FJ.

Leuk Res. 2004 Jul;28(7):679-89.

PMID:
15158089
40.

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.

Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantarjian HM, Stopeck AT.

Cancer. 2003 Apr 15;97(8):1920-8.

41.

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.

Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE.

Blood. 2003 Aug 1;102(3):795-801. Epub 2003 Mar 20.

42.

Radial fast spin-echo method for T2-weighted imaging and T2 mapping of the liver.

Altbach MI, Outwater EK, Trouard TP, Krupinski EA, Theilmann RJ, Stopeck AT, Kono M, Gmitro AF.

J Magn Reson Imaging. 2002 Aug;16(2):179-89.

PMID:
12203766
43.

Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast.

Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, Hersh EM.

J Immunol. 2002 Aug 15;169(4):1829-36.

44.

Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.

Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, Gonzalez R.

Clin Cancer Res. 2001 Aug;7(8):2285-91.

45.
46.

Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.

Stopeck AT, Gessner A, Miller TP, Hersh EM, Johnson CS, Cui H, Frutiger Y, Grogan TM.

Clin Cancer Res. 2000 Oct;6(10):3904-9.

47.

Studies of direct intratumoral gene transfer using cationic lipid-complexed plasmid DNA.

Clark PR, Stopeck AT, Ferrari M, Parker SE, Hersh EM.

Cancer Gene Ther. 2000 Jun;7(6):853-60.

48.

Construction of new amplifier expression vectors for high levels of IL-2 gene expression.

Tsang TC, Brailey JL, Vasanwala FH, Wu RS, Liu F, Clark PR, Meade-Tollin L, Luznick L, Stopeck AT, Akporiaye ET, Harris DT.

Int J Mol Med. 2000 Mar;5(3):295-300.

PMID:
10677573
49.

Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.

Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, Akporiaye ET, Rinehart JJ, Edmonson J, Sobol RE, Forscher C, Sondak VK, Lewis BD, Unger EC, O'Driscoll M, Selk L, Rubin J.

J Clin Oncol. 1999 Oct;17(10):3313-23.

PMID:
10506635
50.

Polycations and cationic lipids enhance adenovirus transduction and transgene expression in tumor cells.

Clark PR, Stopeck AT, Brailey JL, Wang Q, McArthur J, Finer MH, Hersh EM.

Cancer Gene Ther. 1999 Sep-Oct;6(5):437-46.

Supplemental Content

Loading ...
Support Center